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ABSTRACT A procedure utilizing reversed-phase high-
performance liquid chromatography is described for the puri-
fication of asialo granulocyte-macrophage colony stimulating
factor (asialo-GM-CSF) from mouse lung-conditioned medi-
um. In the purification, the partially purified factor was treat-
ed with neuraminidase to reduce charge heterogeneity due to
variable degrees of sialation. Three active forms of the asialo
factor were separated by the final reversed-phase liquid chro-
matography step. These each gave a single major band and
several minor bands on polyacrylamide gel electrophoresis and
had similar amino acid compositions. The specific activity of
purified murine asialo-GM-CSF was approximately 8 x 109
colonies per mg of protein. Amino acid sequence determina-
tion of the major form gave a single amino-terminal sequence,
which has been used to develop oligonucleotide probes for the
isolation of two cDNA clones encoding GM-CSF. The nucleo-
tide sequence of these two clones gave a deduced amino acid
sequence almost identical with that determined for the amino
terminus of asialo-GM-CSF and an amino acid composition
very similar to that for asialo-GM-CSF.
Granulocyte-macrophage colony stimulating factor (GM-
CSF) is a glycoprotein that is required for the in vitro prolif-
eration and differentiation of precursor cells to give colonies
of granulocytes and macrophages (1-4). Comparable hemo-
poietic regulatory factors are macrophage CSF (M-CSF; ref.
5), granulocyte CSF (G-CSF; ref. 6), multi-CSF (ref. 7; also
called interleukin-3 or IL-3, see ref. 8) and erythropoietin
(9), which regulates the formation of erythrocytes. These
proteins have proved difficult to purify because of their low
abundance and carbohydrate heterogeneity; this has general-
ly prevented more than a few micrograms of any of these
growth factors from being purified. Recently, preliminary
amino acid sequence information was obtained for multi-
CSF (IL-3) (10), and the subsequent molecular cloning of the
cDNA coding for this protein (11) has yielded the full amino
acid sequence.
The identification and structural analysis of both mouse
and human GM-CSF genes and their related products are
essential steps in the understanding of the mechanism of ac-
tion of the hemopoietic regulators and their role in the etiolo-
gy of leukemia (12). The amino acid sequence data for mu-
rine GM-CSF, reported here, has aided in the identification
ofcDNA clones for this molecule (13) and should eventually
lead to the isolation of the corresponding genes encoding
GM-CSF.
A purification of GM-CSF from mouse lung-conditioned
medium (MLCM) has been reported (14). This used a num-
ber of conventional chromatographic steps, followed by pre-
parative PAGE, and led to apparently homogeneous niaterial
as judged by PAGE in both denaturing and nondenaturing
conditions. However, the small amount of material available
prevented the effective structural analysis of this molecule.
GM-CSF has a broad isoelectric range from 4.1 to 5.2 due
largely to heterogeneity in glycosylation, specifically siala-
tion; treatment with neuraminidase greatly reduces the
charge heterogeneity and raises the pl from 5.2 to 5.5 (15).
Incorporation of neuraminidase treatment in the purification
protocol thus significantly improves the efficiency of
charge-dependent separation steps.
This report describes the purification of asialo-GM-CSF
from MLCM by an improved protocol incorporating a neur-
aminidase treatment and using reversed-phase HPLC (RP-
HPLC) as a final step instead of preparative gel electropho-
resis. The purified factor is essentially homogeneous by
PAGE and yielded a unique amino-terminal amino acid se-
quence for murine GM-CSF.
MATERIALS AND METHODS
Unless otherwise specified, all buffers contained Triton X-
100 (0.01%, wt/vol), and all operations were carried out at
40C. MLCM was prepared as described (14) by using the
lungs from C57BL mice previously treated with endotoxin
(16).
Purification of Asialo-GM-CSF. MLCM (10.5 liters) was
subjected, in three approximately equal batches, to heat and
then dialyzed against water and fractionated on calcium
phosphate gel as described (15). Two of the three batches
also were carried through ion-exchange chromatography on
DEAE-cellulose as described (14). The three batches then
were combined, concentrated by ultrafiltration in a Diaflo
cell using a YM10 membrane (Amicon), and dialyzed against
0.2 M sodium acetate, 1 mM in Ca2+, Mg2+, and Mn2+, pH
5.0, to give partially processed conditioned medium.
Concanavalin A-Sepharose Chromatography. The partially
processed conditioned medium was then chromatographed
on a column of concanavalin A-Sepharose (1.5 x 27 cm;
Pharmacia) as described (14).
Neuraminidase Treatment. The glycoproteins that bound
to concanavalin A-Sepharose were eluted with a solution of
0.05 M a-methyl mannoside in the above buffer, concentrat-
ed by ultrafiltration, and dialyzed in the Diaflo cell against
0.05 M sodium acetate (pH 5.0). The proteins then were in-
cubated overnight at 37°C with neuraminidase from Clostrid-
ium perfringens (type X; Sigma) at a protein-to-enzyme ratio
of 10 mg/unit of enzyme activity. At this stage material from
a separate preparation, starting with 3 liters of MLCM and
Abbreviations: CSF, colony stimulating factor; GM-CSF, granulo-
cyte (G)-macrophage (M) CSF; MLCM, mouse lung-conditioned
medium; RP-HPLC, reversed-phase HPLC; > PhNCS, phenylthio-
hydantoin.
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taken through the same purification steps, was combined
with the above material.
DEAE-Cellulose Chromatography. The neuraminidase-
treated material was dialyzed against 0.01 M Tris chloride
(pH 7.4) and chromatographed on a column of DEAE-cellu-
lose (1.5 x 80 cm, Whatman DE-52) equilibrated with the
same buffer. After sample application, the column was elut-
ed with 200 ml of the same buffer, followed by a linear gradi-
ent of 0-0. 17 M sodium chloride in a total volume of 1000 ml
of the same buffer at a flow rate of 8 ml/hr. Finally, the
column was eluted with 0.5 M sodium chloride in the same
buffer.
Gel Filtration. Active fractions were combined, concen-
trated to a small volume, and loaded on a column of Ultrogel
AcA44 (LKB) (2.3 x 140 cm) equilibrated with 0.01 M Tris
chloride/0.05 M sodium chloride, pH 7.4, and eluted with
the same buffer at a flow rate of 8.5 ml/hr. Active fractions
were then concentrated in a Diaflo cell (YM10 membrane)
for fractionation by RP-HPLC.
Reversed-Phase HPLC. A Waters Associates HPLC sys-
tem consisting of two M6000A pumps, an M660 solvent pro-
grammer, a U6K injector, an M450 detector and a ,u-Bonda-
pak C18 column (3.9 x 300 mm) was used for the chromatog-
raphy. Separations were performed at ambient temperature
at a flow rate of 1 ml/min. Fractions were collected manual-
ly in siliconized glass tubes, and aliquots were removed and
diluted into fetal calf serum (5%, vol/vol) in sodium chloride
(0.9%) solution for assay.
PAGE. NaDodSO4/PAGE was carried out by the method
of Laemmli (17). Gel slabs were 0.7 mm thick and contained
15% (wt/vol) acrylamide. Samples were heated for 2 min at
100'C in sample buffer (no reductant) before loading. Silver
staining was carried out by the method of Merril et al. (18).
Biological Assay for GM-CSF Activity. This was carried out
as described (14, 19) by determining G-M colony formation
in cultures of 75,000 C57BL bone marrow cells.
Protein Estimation. Protein was estimated during the puri-
fication by the method of Lowry et al. (20), with bovine se-
rum albumin as a standard. The protein yield for purified
GM-CSF was determined by amino acid analysis.
Amino Acid Analysis.. Aliquots of protein (-20 pm) were
hydrolyzed for 24 hr at 1100C in 6 M HCO containing 0.1%
phenol and analyzed with a fluorescence-based amino acid
analyzer using o-phthalaldehyde (21). No corrections were
made for losses of serine or threonine during hydrolysis.
Amino-Terminal Sequence Analysis. Amino-terminal se-
quence determination was carried out on a gas-phase se-
quencer as described by Hewick et al. (22). Protein in 0.1%
CF3COOH/H20/acetonitrile from the RP-HPLC was dried
down in a siliconized glass tube for transport from Mel-
bourne to Los Angeles. The tube was then extracted with, in
order, 60 ,ul of 1% NaDodSO4, 30 ,ul of distilled water, and
60 ,ud of 25% CF3COOH. All extractions were loaded onto
the precycled glass filter, air dried, and loaded into the se-
quencer for analysis. Identification of phenylthiohydantoin
(> PhNCS)-amino acid derivatives was carried out by HPLC
(23).
RESULTS
Neuraminidase Treatment of GM-CSF. Treatment of
MLCM with neuraminidase from Cl. perfringens yielded a
CSF with a higher and narrower isoelectric range (unpub-
lished data) with less polydispersity (unpublished data) than
that of untreated MLCM. The isoelectric range for untreated
GM-CSF was -4.1-5.2, whereas the bulk of the neuramini-
dase-treated material focused between pH 5.2 and 5.5. Com-
parison of the morphology of cells (24) in colonies stimulated
by GM-CSF or asialo-GM-CSF showed no significant differ-
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FIG. 1. Elution profile for chromatography on DEAE-cellulose.
Aliquots (20 ,ul) were removed from every fifth fraction (8 ml) for
biological assay (shaded columns). Absorbance at 280 nm (-) was
measured with distilled water as reference. Fractions were pooled as
indicated (I 1) ------, Applied salt gradient.
ence, indicating that the in vitro biological activity of the two
molecular species was identical.
Purification of Asialo-GM-CSF. The purification of asialo-
GM-CSF was based on the previously described method (14)
in which the major fractionation steps were chromatography
on DEAE-cellulose, concanavalin A-Sepharose, and Ultro-
gel AcA44, followed by preparative PAGE. In order to re-
duce contaminating protein as far as possible before neur-
aminidase treatment, fractionation on concanavalin A-Seph-
arose was carried out first, followed by neuraminidase
treatment and then chromatography on DEAE-cellulose and
Ultrogel AcA44; preparative PAGE was replaced by RP-
HPLC. The elution profile for DEAE-cellulose chromatog-
raphy of neuraminidase-treated material is shown in Fig. 1,
while that for the gel filtration of the resulting active frac-
tions, indicating an apparent Mr of 33,000 [cf., a value of
29,000 in a previous study (14)], is shown in Fig. 2. The elu-
tion profile for the final RP-HPLC step is shown in Fig. 3.
The complete purification of asialo-GM-CSF starting from
step 2 MLCM is summarized in Table 1. Material from two
separate preparations was combined after the neuraminidase
treatments; however, the total activity at this stage was sig-
nificantly higher than expected (shown in parentheses in Ta-
ble 1) from the activities of the separate preparations. As
neuraminidase treatment does not change the in vitro activi-
ty (15), this discrepancy may be due to variability in the bio-
assays, which also would have been responsible for the
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FIG. 2. Elution profile for gel filtration on Ultrogel AcA44. Ali-
quots (10-i1) were removed from every second fraction (4 ml) for
biological assay (shaded columns). Absorbance at 280 nm (-) was
measured with distilled water as reference. Fractions were pooled as
indicated (I -). Molecular weight markers were: V0, blue dextran;
1, bovine serum albumin (67,000); 2, ovalbumin (43,000); 3, chymo-
trypsinogen A (26,000).
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FIG. 3. Purification of asialo-GM-CSF by RP-HPLC of pooled
active fractions from Ultrogel AcA44 chromatography. Buffers: A,
20% acetonitrile/0.05% CF3COOH; B, 80% acetonitrile/0.05%
CF3COOH. Concentrated, active fractions (500 ,l) were injected
onto the column, which was equilibrated at 25% buffer B. ------, Ap-
plied solvent program. Aliquots (20 td) were removed from each
fraction for biological assay (shaded columns). (Inset) NaE)odSO4/
PAGE of active fractions A, B, and C from the RP-HPLC step; 5-
10%6 of each fraction was dried down before dissolving in sample
buffer as described.
slight increase in activity between steps 4 and 5.
Asialo-GM-CSF separated as a complex peak on RP-
HPLC. When the most active fractions (A, B, and C) were
subjected to NaDodSO4/PAGE (Fig. 3 Inset), all showed a
single major band and several minor bands of silver-stained
protein, The position of the major bands was comparable
with that demonstrated for the biological activity in a previ-
ous study (14). However, the major bands (A, B, and C)
from the three RP-HPLC fractions (Fig. 3) differed slightly
in their mobility on NaDodSO4 gels, and that for fraction B
was significantly heavier than those for A and C, although
approximately equal protein loads were used for each track.
Fraction B had the highest specific activity and was obtained
in a final yield of 14%. The total yield for A, B, and C was
27%.
Aliquots of each of A, B, and C were subjected to amino
acid analysis. The remainders of A and C were utilized for
further chromatographic experiments, while that for B was
subjected to amino-terminal sequence analysis.
Amino Acid Composition of Asialo-GM-CSF. The amino
acid composition of asialo-GM-CSF was determined after
OCi hydrolysis of suitable aliquots of fractions A, B, and C.
The analyses were carried out on a fluorescence-based ami-
no acid analyzer and, because of the inherent limitations of
this system, failed to provide values for proline and trypto-
phan. Values for methionine and cysteine also were not ob-
tained because of the difficulties of amino acid analysis at
high sensitivity. The limited amino acid composition of
asialo-GM-CSF (fractions A, B, and C) is shown in Table 2.
Amino-Terminal Sequence Analysis of Asialo-GM-CSF.
The remainder of fraction B, amounting to -300 pmol of
protein by amino acid analysis, was subjected to amino acid
sequence analysis with a gas-phase sequencer. A single ami-
no acid sequence could be clearly read for 34 residues with
31 residues being readily assigned (Fig. 4, rows a). The ami-
no-terminal residue itself could not be identified, as >
PhNCS derivatives of isoleucine, valine, and serine were all
evident after the first cycle. The yields of > PhNCS-amino
acid derivatives identified for each position throughout this
run are shown in Fig. 5, which also shows that the initial
yield was only 20 pmol while the repetitive yield was 95.5%.
It should be noted that, due to adsorptive losses, only 50
pmol of the original 300-mol sample was recovered from the
siliconized glass tube.
DISCUSSION
Structural studies on GM-CSF have been hampered by lack
of material because of the extremely small amounts of active
protein in each of the richest sources. The purification de-
scribed above yielded a preparation (fraction B) with a spe-
cific activity of 7.9 x 109 colonies per mg that gave essential-
ly a single band on NaDodSO4/PAGE and yielded a single
amino acid sequence. The material from the earlier purifica-
tion protocol (14), which also gave a single band on NaDod-
S04/PAGE, had a specific activity of -7 x 107 colonies per
mg. Comparison of the two different purification protocols
shows the major difference to be the increased efficiency of
RP-HPLC (x 40 purification) compared to preparative
PAGE (x 2 purification) as the final step. The different order
of steps in the two protocols makes it difficult to directly
assess the effect of neuraminidase treatment on the efficien-
cy of the ion-exchange fractionation.
Using oligonucleotide probes derived from the partial ami-
no acid sequence of asialo-GM-CSF (Fig. 4, rows a), Gough
et al. (13) have isolated two cDNA clones from a mouse lung
Table 1. Purification of asialo-GM-CSF from MLCM
Volume, Total Total activity, Specific activity,
Fraction ml protein, mg Col x 10-6 Col x 10-6 per mg
1 Partially processed conditioned medium 212 763 848 1.1
2 Concanavalin A-Sepharose-bound protein 10 190 565 3.0
3 Neuraminidase treatment* 22.5 315 1499 4.8
(936)t (3.0)t
4 DEAE-cellulose 6.2 56 426 7.6
S Ultrogel AcA44 1.6 3.0 529 176
6 RP-HPLCt
A 2.7 0.011§ 33.8 3000
B 2.0 0.007§ 58.8 7900
C 3.0 0.011§ 24.2 2100
Col, GM colony formation.
*Material from two separate preparations combined at this step.
tCalculated from the activities of the separate preparations at step 2.
fFrom 0.5 ml of step 5 material.
§By amino acid analysis.
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Table 2. Amino acid composition of GM-CSF
Fractions from
RP-HPLC
Amino acid
Lys
His
Arg
Trp
Cys
Asp
Thr
Ser
Glu
Pro
Gly
Ala
Val
Met
Ile
Leu
Tyr
Phe
A B C From cDNA
8.0
1.8
5.1
ND
ND
11.3
9.6
9.6
14.0
ND
8.1
7.6
6.5
ND
4.5
7.3
3.7
6.8
9.9
2.3
4.9
ND
ND
9.1
12.2
6.5
15.9
ND
6.8
7.0
6.3
ND
4.3
9.3
3.4
6.1
8.7
2.3
5.3
ND
ND
10.5
10.0
7.7
15.1
ND
8.9
6.3
7.3
ND
3.3
9.7
3.4
5.4
11
1
3
1
4
11
14
5(4)*
15
7
3(4)*
8
2
6
11
4
7
Amino acid compositions are calculated as residues per mole (118
residues) assuming values for cysteine, methionine, proline, and
tryptophane from the cDNA sequence (13). ND, not determined.
*Uncertainties in these values are due to ambiguities in the cDNA
sequence.
cDNA library and have demonstrated that these encode mu-
rine GM-CSF. From the nucleotide sequence of these
clones, the complete amino acid sequence of GM-CSF has
been deduced; the first 34 residues of this deduced sequence
are shown in Fig. 4, rows b. This sequence is essentially
identical for the first 34 residues with that obtained by direct
protein sequencing. At three positions, 1, 24, and 32, no
> PhNCS-amino acid derivative could be assigned. The
cDNA-derived amino acid sequence shows isoleucine at po-
sition 1, which is consistent with the > PhNCS derivative of
isoleucine being among the > PhNCS-amino acid deriva-
tives identified after the first sequencing cycle. At position
32, the > PhNCS derivative of glutamic acid was identified
but was ascribed to overlap from glutamic acid at positions
29 and 30.
The two sequences differ at two other positions, 2 and 4,
underlined in Fig. 4. After cycle 2, the > PhNCS derivatives
of threonine and isoleucine were both present, but because
the derivative of isoleucine was also identified after cycle 1,
its presence at cycle 2 was ascribed to carry over and ig-
nored. After cycle 4, the > PhNCS derivative of glutamic
acid was obtained but no > PhNCS derivative of threonine,
as expected from the cDNA sequence, and there seems to be
10
a ? Thr Val Glu Arg Pro Trp Lys His Val Glu Ala Ile
b Ile Ile Val Thr Arg Pro Trp Lys flis Val Clu Ala Ile
20
a Lys Clu Ala Leu Asn Leu Leu Asp Asp Met ? Val Thr Leu
b Lys Clu Ala Leu Asn Leu Leu Asp Asp Met Pro Val Thir Leu
30
a Asn G]lu GCl Val ? Val Val
b Asn Glu Glu Val Clu Val Val
FIG. 4. Amino-terminal sequence of GM-CSF. Rows: a, deter-
mined on gas-phase sequencer; b, deduced from the sequence of
cDNA clones pGM37 and pGM38 (13). Differences between the two
sequences are underlined; ? indicates no assignment made.
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FIG. 5. Yields of> PhNCS-amino acid derivatives identified
during sequences of asialo-GM-CSF.
a genuine difference between the two sequences at position
4. Threonine 4 may be modified post-translationally to give
an amino acid residue mistakenly identified as glutamic acid
during protein sequencing, or perhaps variants of this mole-
cule exist in the mouse population. Such variants could arise
through multiple alleles or through polymorphism at a single
allele. However, Gough et al. (13) have shown that multiple
alleles of the GM-CSF gene do not exist in the murine
genome.
The amino acid composition of GM-CSF, deduced from
the nucleotide sequence, is shown in Table 2. There is quali-
tative agreement between this composition and that deter-
mined for asialo-GM-CSF by direct amino acid analysis of
fractions A, B, and C from RP-HPLC. Discrepancies in the
values for arginine and glycine can be explained by baseline
variations in the arginine region of the amino acid chromato-
gram and the presence of glycine as a common contaminant
in our laboratory at the time. The amino acid compositions
of fractions A and C are qualitatively the same as that for
fraction B, given the limitations of the technique. Fractions
A and C also showed substantial biological activity, and gave
each a single band on NaDodSO4/PAGE (Fig. 3); the major
bands for fractions A, B, and C are all slightly different in
mobility on NaDodSO4/PAGE. However, the specific activ-
ities of fractions A and C are significantly lower than that of
fraction B. The similarity in amino acid compositions of the
three fractions suggests that they are three forms of asialo-
GM-CSF, differing in relative activities. Multiple forms of
native GM-CSF, separable by RP-HPLC or NaDodSO4/
PAGE, have been observed (unpublished data). The differ-
ences between these forms appear to reside in differences in
the patterns of glycosylation, which also may be responsible
for the differential silver staining of the three forms.
Comparison of the amino acid composition and the partial
amino acid sequence of fraction B with the composition and
sequence of GM-CSF derived from the two cDNA clones
(13) confirms that the protein isolated and sequenced in this
study is, in fact, asialo-GM-CSF. Such confirmation is par-
ticularly important in view of the low yield at cycle 1 of the
sequencer run, although low initial yields during sequencer
runs are well documented (25). The agreement in the amino
acid compositions shows that GM-CSF is the predominant
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protein of fraction B, rather than a minor component in a
mixture with an amino-terminally blocked protein not de-
tected in amino acid sequencing.
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